<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190203042608N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-12-29</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the Effect of Adherence to Therapeutic Regimen program on the Quality of Life in Patients with Atrial Fibrillation</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the Effect of Adherence to Therapeutic Regimen program on the Quality of Life in Patients with Atrial Fibrillation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-01-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/42319</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: To collect data, having obtained the required permissions accompanied with the authorities’ agreement and cooperation, the researcher refers to the CCU, Post CCU, and internal cardiology units of the Chamran Hospital and extracts the list of patients with atrial fibrillation arrhythmia introduced by the cardiologist specialists in these units. Then, she talks to all patients having the inclusion criteria, and, in addition to introducing herself, she explains them the purpose of the study. Finally, the qualified samples for the study are simply selected, and, having acquired their written informed consent, we will include them in the study. The randomization is implemented as the following: the samples are given numbers from the list of random numbers, and, according to the numbers, the even ones are assigned to the experimental group and the odd ones are assigned to the control group. This task continues until the considered sample number is achieved.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Atrial Fibrillation.</hc_freetext>
      <i_freetext>Intervention 1: A compiled therapeutic regimen program which is a synthesis of personal training and practicing in two 45-minute successive sessions. On the second and third days of hospitalization, during the hours 9 to 11, and with the aid of illustrated pictures of an educational booklet, there will be face to face discussions between the patients and the researcher on the arrhythmia type, the therapeutic method, the used drugs and their side effects, the amount of activity, how to face psychological problems, the significance of conducting coagulation tests, the type of nourishing, and a plan to correctly face probable problems. At the end of the second session, the experimental group will be given an educational booklet concerning the presented issues in adherence to a therapeutic regimen program. The telephone call happens between 8 in the morning and 8 at night on certain dates and times according to the agreement between the researcher and the patient and its content is encouraging the presented discussions in the sessions, question and answer, reinforcing the lessons, and the disease management power. Then, there will be no intervention for 8 weeks. Finally, 12 weeks after the intervention, the questionnaire will be filled out by the educational colleague. Intervention 2: Control group: This group will receive the usual cares besides a personal 30-minute session concerning the atrial fibrillation disease. One month after the intervention, a researcher colleague possessing no information on the study purposes will fill out the questionnaire via the questioning method and by the use of data included in the histories of the experimental and control groups.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The entire data present in the questionnaire is sharable after it becomes unidentifiable

When:
The accessibility onset is up to 5 years after printing the results

To whom:
It will be accessible to all researchers working in scientific and academic institutions

Conditions:
The resultant documents can be referred to in similar studies on the patients with atrial fibrillation, the effect of regimen according to demographic variables, and similar issues

Where to obtain:
Referring to the library of the nursing faculty and receiving the electronic file of the thesis
The personal e-mail of the researcher Fatima Yazdizadeh: yazdizadeh.f71@gmail.com

How to obtain:
The document appliers should have valid student number from their university or ethics code from the respected university. Moreover, they should present the full specifications of their advisors while they receive the documents so that they can hold them for two weeks.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Yazdizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Number 5, Palestine Boulevard the 16th</address>
        <city>Shirvan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9461658685</zip>
        <telephone>+98 83 3835 8258</telephone>
        <email>yazdizadeh.f71@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Yazdizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Number 5, Palestine Boulevard the 16th</address>
        <city>Shirvan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9461658685</zip>
        <telephone>+98 936 845 2985</telephone>
        <email>yazdizadeh.f71@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>7-	The Main Inclusion criteria in the Study before Randomization Those patients with atrial fibrillation arrhythmia diagnosed and treated by cardiologist specialists.
Those patients with atrial fibrillation arrhythmia hospitalized for the first time.
Those patients that are in the age range between 35 and 70 years old</inclusion_criteria>
      <agemin>35 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients’ disinclination to participate in the intervention
Patients’ with physical and psychological problems leading to their disabilities
3.	Patients below 35 years old and above 70 years old</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I48.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Persistent atrial fibrillation</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Diagnosis</i_code>
      <i_code>Diagnosis</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>A compiled therapeutic regimen program which is a synthesis of personal training and practicing in two 45-minute successive sessions. On the second and third days of hospitalization, during the hours 9 to 11, and with the aid of illustrated pictures of an educational booklet, there will be face to face discussions between the patients and the researcher on the arrhythmia type, the therapeutic method, the used drugs and their side effects, the amount of activity, how to face psychological problems, the significance of conducting coagulation tests, the type of nourishing, and a plan to correctly face probable problems. At the end of the second session, the experimental group will be given an educational booklet concerning the presented issues in adherence to a therapeutic regimen program. The telephone call happens between 8 in the morning and 8 at night on certain dates and times according to the agreement between the researcher and the patient and its content is encouraging the presented discussions in the sessions, question and answer, reinforcing the lessons, and the disease management power. Then, there will be no intervention for 8 weeks. Finally, 12 weeks after the intervention, the questionnaire will be filled out by the educational colleague.</i_keyword>
      <i_keyword>Control group: This group will receive the usual cares besides a personal 30-minute session concerning the atrial fibrillation disease. One month after the intervention, a researcher colleague possessing no information on the study purposes will fill out the questionnaire via the questioning method and by the use of data included in the histories of the experimental and control groups</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The quality-of-life in patients with atrial fibrillation in the AFEQT questionnaire. Timepoint: Investigating the quality of life at the study outset, one month and three months after the intervention. Method of measurement: The atrial fibrillation effect on the quality-of-life questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The atrial fibrillation symptoms including heartbeat, chest pain, shortness of breath, and vertigo. Timepoint: All items accomplished before the intervention, and one month and three months after the intervention. Method of measurement: All items are from the atrial fibrillation effect on the quality-of-life questionnaire for the patients with atrial fibrillation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-01-14</approval_date>
        <contact_name>The Ethics Committee of Isfahan, University of Medical Sciences</contact_name>
        <contact_address>The Headquarters, Isfahan, University of Medical Sciences and Healthcare Services, Hezarjarib Street Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
